[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"branding":3,"analytics":7,"article-fda-orders-eye-risk-warning-on-ozempic-wegovy-other-glp-1s":10,"sections":50},{"siteName":4,"siteTagline":5,"publisherName":4,"contactEmail":6},"The Revision","Tech news, decoded.","editor@therevision.news",{"gaMeasurementId":8,"adsenseClientId":9},"G-ZW2MV82GYR","ca-pub-8533917693782264",{"article":11},{"id":12,"slug":13,"title":14,"dek":15,"body_md":16,"tags_json":17,"published_at":18,"created_at":19,"updated_at":20,"status":21,"review_note":22,"review_notes":23,"image_url":22,"persona_id":22,"persona_name":22,"section":39,"tags":40,"sources":45,"feedback":49,"feedback_at":22,"cost_usd":49,"total_tokens":49},12725,"fda-orders-eye-risk-warning-on-ozempic-wegovy-other-glp-1s","FDA Orders Eye-Risk Warning on Ozempic, Wegovy, Other GLP-1s","The FDA will require GLP-1 labels to flag a possible link to NAION, a rare optic nerve condition that can cause permanent vision loss.","The FDA will require makers of GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, to add a warning about a \"potential increased risk\" of a rare eye condition that can cause permanent vision loss.\n\nThe agency announced the change in a drug safety communication on Monday. The condition is non-arteritic anterior ischemic optic neuropathy, or NAION. It starts when blood flow to the optic nerve is restricted, which causes swelling and cell death. The result is abrupt vision loss that can often be permanent. How GLP-1 drugs might trigger it is unknown.\n\nNAION is uncommon. According to the American Academy of Ophthalmologists, it occurs in somewhere between two and 10 people per 100,000 in the general population. Cases that rare are hard to count, and that makes a connection to any single drug hard to confirm.\n\nA second problem is overlap. The risk factors for NAION include diabetes, cardiovascular disease, high blood pressure, high cholesterol, metabolic syndrome and obstructive sleep apnea. Those are common among people who take GLP-1 drugs, so it is hard to separate what the drugs do from what the underlying conditions do.\n\nThat context shapes how to read the label change. The FDA's wording is \"potential,\" and the mechanism is unexplained. A label warning in this setting looks like a precaution taken while the evidence is incomplete, not a finding that the drugs cause NAION. The open question is whether further data can pull the drugs' effect apart from the health conditions that so often come with them.","[\"fda\",\"glp-1\",\"drug-safety\",\"health\"]","2026-11-10T14:43:49.000Z","2026-11-10T15:31:55.579Z","2026-11-10T15:31:55.825Z","published",null,[24,30,35],{"id":25,"reviewer":26,"round":27,"reason":28,"status":29},"editor-r1","editor",1,"Fix three problems: (1) the source says only that the FDA communication came 'Monday', so remove the invented 'November 9' date or use 'Monday'; (2) delete the source-meta phrasing 'The source says these are common among people taking GLP-1 drugs' and state the point directly; (3) cut or support the claim that the communication 'gives no estimate' of increased risk, since the source doesn't say that and the hedge 'as described' is an unresolved editing note.","resolved",{"id":31,"reviewer":32,"round":33,"reason":34,"status":29},"publisher-r2","publisher",2,"The body contains a grammatical error (\"a established cause\" should be \"an established cause\") and misnames the source organization as the \"American Academy of Ophthalmologists\" instead of the American Academy of Ophthalmology, so both need fixing before publication.",{"id":36,"reviewer":26,"round":37,"reason":38,"status":29},"editor-r3",3,"The draft gives the FDA communication date as 'November 9', which the source never states (it says only 'Monday') and which may not fall on a Monday, so use the source's wording or verify the date; also drop or support the claim that 'the FDA has not put a number on the added risk', which the source does not say.","science",[41,42,43,44],"fda","glp-1","drug-safety","health",[46],{"name":47,"url":48},"Ars Technica","https:\u002F\u002Farstechnica.com\u002Fhealth\u002F2026\u002F11\u002Fglp-1-drugs-may-increase-risk-of-vision-loss-from-rare-condition-fda-warns\u002F",0,{"sections":51},[52,57,62,67,72,77,82,86,91,96,101,106,111,116],{"name":53,"slug":54,"count":55,"latest_published_at":56},"AI","ai",7144,"2026-11-12T13:27:45.000Z",{"name":58,"slug":59,"count":60,"latest_published_at":61},"Security","security",1128,"2026-11-11T18:05:00.000Z",{"name":63,"slug":64,"count":65,"latest_published_at":66},"Deals","deals",642,"2026-11-12T14:00:00.000Z",{"name":68,"slug":69,"count":70,"latest_published_at":71},"Policy","policy",619,"2026-11-12T12:53:36.000Z",{"name":73,"slug":74,"count":75,"latest_published_at":76},"Consumer Tech","consumer-tech",364,"2026-11-12T11:12:32.000Z",{"name":78,"slug":79,"count":80,"latest_published_at":81},"Hardware","hardware",336,"2026-11-12T11:24:43.000Z",{"name":83,"slug":39,"count":84,"latest_published_at":85},"Science",230,"2026-11-12T10:00:00.000Z",{"name":87,"slug":88,"count":89,"latest_published_at":90},"Software","software",168,"2026-11-11T17:36:49.000Z",{"name":92,"slug":93,"count":94,"latest_published_at":95},"Startups","startups",159,"2026-11-11T12:30:00.000Z",{"name":97,"slug":98,"count":99,"latest_published_at":100},"Dev Tools","dev-tools",127,"2026-11-11T19:00:44.000Z",{"name":102,"slug":103,"count":104,"latest_published_at":105},"General","general",118,"2026-11-11T16:49:42.000Z",{"name":107,"slug":108,"count":109,"latest_published_at":110},"Gaming","gaming",107,"2026-11-12T10:09:03.000Z",{"name":112,"slug":113,"count":114,"latest_published_at":115},"Reviews","reviews",38,"2026-10-20T12:00:00.000Z",{"name":117,"slug":118,"count":119,"latest_published_at":120},"How-To","how-to",8,"2026-10-05T09:00:00.000Z"]